Is Taking Insulin Bad for You? Weighing the Risks

Insulin is not inherently harmful. For anyone whose body cannot produce enough of it, insulin therapy is the single most effective way to control blood sugar and prevent the organ damage that uncontrolled diabetes causes over time. But like virtually every powerful medication, insulin carries real risks, and pretending those risks don’t exist helps no one. The most common dangers are well understood and largely manageable, yet they do require attention, and a few remain the subject of genuine scientific debate.

Low Blood Sugar Is the Biggest Day-to-Day Risk

Hypoglycemia, or a blood sugar drop below the normal range, is the most frequent and most feared side effect of insulin therapy. It can cause shakiness, confusion, sweating, and irritability in mild cases. In severe cases it leads to seizures, loss of consciousness, and emergency-room visits. Insulin-induced low blood sugar accounts for roughly 100,000 emergency department calls per year in the United States alone.¹ Those numbers include both accidental and intentional overdoses, but even a routine miscalculation of a mealtime dose or an unexpectedly long walk can trigger an episode.

Hypoglycemia is not an argument against insulin. It is an argument for careful dosing, regular monitoring, and access to fast-acting glucose sources. Most people on insulin learn to recognize the early warning signs and correct a mild low within minutes. The risk rises when doses are too aggressive, meals are skipped, alcohol is consumed, or kidney function changes, all situations where dose adjustments can help.

When You Stop Feeling the Lows

A subtler and more dangerous pattern can develop over time. Repeated episodes of hypoglycemia can dull the body’s alarm system, a condition sometimes called hypoglycemia unawareness. Normally, when blood sugar drops, your body releases stress hormones like adrenaline that produce obvious symptoms: a racing heart, sweating, hunger. These symptoms are your cue to eat something. But when low blood sugar happens over and over, the threshold at which those hormones kick in shifts downward. The result is a vicious cycle: you don’t feel the warning signs, so you don’t correct the low, and the next episode arrives unannounced too.²

Research going back to the 1990s showed that even a single afternoon episode of hypoglycemia could blunt the body’s hormonal defenses the following morning, raising the threshold at which warning symptoms appear.³ The causes are multifactorial: chronic exposure to low blood glucose, failure of counter-regulatory hormones, and recurrent severe episodes all contribute.⁴ The good news is that this condition is at least partly reversible. Scrupulously avoiding hypoglycemia for several weeks can restore awareness in many people, allowing the hormonal alarm system to recalibrate.

Weight Gain on Insulin

Many people notice the number on the scale creep upward after starting insulin, and this is one of the most common reasons patients resist or delay the therapy. The weight gain is real, but its causes are more nuanced than “insulin makes you fat.” Before insulin treatment, poorly controlled diabetes often means glucose is being lost in the urine. Once insulin brings blood sugar back under the kidney’s threshold for spilling glucose, those calories stay in the body. If you don’t reduce calorie intake to match, weight goes up.⁵

There is also a behavioral component. Low blood sugar episodes trigger hunger and often lead to defensive snacking, eating extra calories “just in case” to avoid another hypoglycemic event. Over months and years, those extra snacks add up. The pharmacokinetics of injected insulin are also less elegant than the body’s own insulin release: a subcutaneous injection delivers insulin in a broad wave rather than a finely tuned pulse timed to what you’re eating, which can encourage fat storage.⁵ None of this is inevitable, though. Dietary counseling, dose optimization, and combination with certain other medications can blunt or offset the gain.

Does Insulin Hurt Your Heart?

Observational studies have sometimes found that people on higher insulin doses have more cardiovascular events: more heart attacks, more strokes. Taken at face value, that sounds alarming. But observational data can be deeply misleading here, because the people who need the most insulin tend to be the sickest patients. They typically have more severe insulin resistance, longer-standing diabetes, and higher body weight, all of which independently raise cardiovascular risk. One large observational analysis noted that its finding of higher cardiovascular events among high-dose insulin users could not account for differences in body mass index, and obesity itself drives a pro-inflammatory, prothrombotic state that worsens cardiovascular outcomes with or without insulin.⁶

When researchers designed a trial to isolate insulin’s effect, the picture changed dramatically. The ORIGIN trial randomized over 12,000 people with early type 2 diabetes or prediabetes to either insulin glargine (a long-acting basal insulin) or standard care and followed them for more than six years. Cardiovascular event rates were virtually identical between the two groups, and insulin glargine had a neutral effect on both heart outcomes and cancer rates.⁷ That trial provides the strongest evidence we have that insulin therapy, when used at appropriate doses, does not independently damage the cardiovascular system.

The Cancer Question

A separate concern has swirled around insulin and cancer risk. The worry stems from biology: insulin, particularly at high concentrations, can bind to receptors in a growth-factor signaling system that helps regulate cell growth and survival.⁸ In lab dishes, certain insulin analogs showed the ability to stimulate cell division in cell lines that express high levels of the IGF-1 receptor, though only at concentrations far above what a normal injection produces in the bloodstream.⁹

In living humans, the evidence is more reassuring but not entirely settled. The ORIGIN trial found no increase in cancer incidence with insulin glargine over six years.⁷ However, a cohort study of patients with type 1 diabetes found that those in the highest daily insulin dose group had a higher cancer incidence than those taking the least insulin, even after adjusting for other factors.¹⁰ The absolute rates were still low, about 2 to 3 cancer cases per 1,000 person-years across all dose groups, so the practical significance for any individual is small. And as with cardiovascular outcomes, observational data cannot easily separate the effect of insulin itself from the metabolic environment of someone who needs a lot of it. The scientific consensus for now is that standard therapeutic doses of modern insulin analogs have not been shown to cause cancer, but the question of whether very high lifetime exposure adds a small increment of risk remains open.

Can Insulin Make Insulin Resistance Worse?

This is a legitimate biological concern, not just internet speculation. Chronically elevated insulin levels, whether from the body’s own production or from injections, can downregulate insulin receptors in muscle tissue. A transcriptomic analysis of over 450 human muscle samples found that higher fasting insulin levels consistently correlated with lower expression of the insulin receptor gene. Lab experiments confirmed that prolonged exposure to elevated insulin reduced receptor protein on cell surfaces and blunted the signaling pathways that allow cells to respond to insulin.¹¹

In plain terms, flooding cells with insulin can make them less responsive to it, potentially requiring even more insulin over time. This is one reason clinicians try to use the minimum effective dose and often pair insulin with other medications that improve insulin sensitivity or reduce how much insulin the body needs. The goal is to keep blood sugar controlled without driving insulin levels higher than necessary.

The Overlooked Upside for the Pancreas

For people with type 2 diabetes who still have some insulin-producing capacity, early insulin therapy can actually protect the cells that make insulin. The logic is counterintuitive: by injecting insulin from outside, you relieve the overworked beta cells in the pancreas, giving them a rest from the constant demand to produce more. This “beta-cell rest” helps preserve their function over time and reduces the toxic effects of chronically high blood sugar on the pancreas itself.¹²

A multicenter trial of patients with newly diagnosed type 2 diabetes found that a short course of intensive insulin therapy led to better recovery and longer maintenance of beta-cell function compared with oral medications alone, and some patients achieved extended remission.¹³ This is a reminder that the risks of insulin need to be weighed against the very real damage that uncontrolled blood sugar inflicts on nerves, kidneys, eyes, and blood vessels. Delaying insulin when it is needed can be far more dangerous than taking it.

Kidney Disease Changes the Math

One group of people who face amplified insulin risk is those with advanced kidney disease. The kidneys play a major role in clearing insulin from the bloodstream. As kidney function declines, insulin sticks around longer, its plasma half-life increases, and the risk of hypoglycemia rises substantially.¹⁴ This is why patients on dialysis or with severely reduced kidney function often need their insulin doses cut by up to half.¹⁵

This isn’t a reason to avoid insulin in kidney disease. It’s a reason to use it more carefully. Frequent blood sugar monitoring, dose reductions, and close collaboration with a clinician who understands the changing pharmacokinetics are essential. The danger is not the insulin itself but treating a patient with kidney impairment as if their body clears insulin at the same rate as everyone else.

What’s Actually in the Vial Besides Insulin

Commercial insulin formulations don’t contain only insulin. They include preservatives, primarily phenol and metacresol, that keep the solution sterile and stable in multi-use vials. These chemicals have biological effects of their own. Lab research found that insulin formulations were toxic to several types of cells and triggered inflammatory signaling, and that the toxicity tracked with the preservative concentration rather than the insulin itself.¹⁶ In rare cases, metacresol has caused allergic-type reactions at injection sites.¹⁷

For most people, these preservatives cause no noticeable problems. But for the small number who develop persistent redness, lumps, or skin reactions at injection sites, the culprit may not be insulin at all but the chemicals mixed in with it. Switching to a different insulin brand with a slightly different excipient profile sometimes resolves the issue, since formulations vary in their preservative concentrations.

How Modern Tools Have Changed the Risk Profile

Many of the risks discussed above were more severe a generation ago. Today’s insulin landscape looks quite different from the one that shaped public perception.

Newer insulin analogs are designed to reduce the unpredictability of older formulations. In a head-to-head study, patients treated with a novel long-acting insulin experienced fewer hypoglycemic episodes overall than those on insulin glargine, with half as many participants experiencing nighttime lows. The newer-analog group spent significantly less time in the hypoglycemic range across 24-hour monitoring periods.¹⁸ These incremental improvements in glucose variability and overnight stability translate to meaningful quality-of-life gains for people who take insulin every day.

Combination therapies have also reshaped the landscape. Adding a GLP-1 receptor agonist to basal insulin consistently improves blood sugar control without the weight gain or extra hypoglycemia that comes with adding mealtime insulin injections. In some cases, GLP-1 agonists produce weight loss rather than gain and allow patients to reduce their total insulin dose.¹⁹ Compared with stacking on more insulin at meals, adding a GLP-1 agonist achieves similar or better blood sugar results with less hypoglycemia and less weight gain.²⁰ Modeling work has estimated that adding GLP-1 receptor agonists or SGLT-2 inhibitors to insulin regimens could reduce daily insulin requirements by roughly 5 to 8 units per day while decreasing cardiovascular complications and mortality.²¹

Continuous glucose monitors have added another layer of safety. By alerting users before blood sugar drops too low, they make it easier to avoid both hypoglycemia and the unawareness cycle that repeated lows can trigger. When paired with insulin pumps in automated “closed-loop” systems, the technology can suspend insulin delivery preemptively, catching dangerous drops before they happen. None of these tools eliminate risk entirely, but they narrow the gap between injected insulin and the body’s own fine-tuned release.

How Older Insulins Compare With Modern Ones

Before recombinant human insulin became available in the 1980s, people injected insulin purified from pig or cow pancreases. These animal-derived insulins differed slightly in structure from human insulin, and the body’s immune system often recognized them as foreign. This triggered antibody production, which could lead to unpredictable absorption, allergic reactions at injection sites, and difficulty controlling blood sugar. Improvements in purification methods reduced these problems over the decades, and the introduction of recombinant human insulin further lowered immune reactions.²² Interestingly, the antibody response triggered by animal insulin persisted for years after switching to human insulin, which meant that for some patients, the immunological legacy of older formulations lingered long after they stopped using them.

The evolution matters because much of the fear surrounding insulin’s risks was formed during an era of cruder formulations, unpredictable absorption, and limited monitoring tools. Someone who heard horror stories about insulin therapy in the 1970s or 1980s is carrying a mental model that no longer matches the current reality. That doesn’t mean modern insulin is risk-free, but the nature and magnitude of the risks have shifted considerably.

The Psychology of Avoiding Insulin

Perhaps the most widespread harm associated with insulin doesn’t come from the drug itself but from the reluctance to use it. Clinicians call this “psychological insulin resistance,” and it is common among people with type 2 diabetes. Patients often interpret a prescription for insulin as a personal failure, a sign that their disease has gotten out of control. Some fear needles. Others worry about the stigma of injecting in public. And many have absorbed a vague cultural message that insulin is dangerous, which leads them to delay starting it for months or years.

The clinical consequence is that many patients spend an extended period with poorly controlled blood sugar while they and their doctors try one oral medication after another, hoping to avoid insulin. During that window, high glucose is silently damaging blood vessels, kidneys, and nerves. Research on early intensive insulin therapy, as noted above, suggests that starting sooner rather than later can preserve beta-cell function and sometimes even induce remission.¹³ Patients with diabetes also face a two- to threefold higher risk of depression compared with the general population, and the emotional burden of managing injections, counting carbs, and worrying about lows can compound that.¹ Mental health support is a legitimate part of insulin therapy, not an optional add-on.

Who Faces the Most Risk From Insulin Therapy

Not everyone on insulin faces the same risk profile. Several groups need extra caution:

Older adults: Reduced kidney function, polypharmacy, and cognitive changes make hypoglycemia both more likely and more dangerous. Many guidelines now recommend less aggressive blood sugar targets for elderly patients to reduce low-blood-sugar events.
People with kidney disease: As discussed earlier, impaired insulin clearance means a standard dose can act like a higher one. Dose reductions and frequent monitoring are standard practice.
Those with hypoglycemia unawareness: Anyone who has experienced repeated lows without warning symptoms should use continuous glucose monitoring if at all possible, since the usual body signals can no longer be trusted.
People who use alcohol regularly: Alcohol suppresses the liver’s glucose production, and combining heavy drinking with insulin can cause prolonged, severe hypoglycemia that is harder to correct.
Patients on tight budgets: Insulin that is rationed, diluted, or skipped because of cost can produce wild swings in blood sugar that are more dangerous than consistent use at the prescribed dose. Access and affordability are safety issues, not just economic ones.

For all of these groups, the solution is not to withhold insulin but to adjust how it is used. Insulin therapy is not one-size-fits-all, and the risks rise when it is treated as though it were.

1
PubMed Central. The Other Face of Insulin-Overdose and Its Effects
2
PubMed Central. Hypoglycemia Unawareness-A Review on Pathophysiology and Clinical Implications
3
PubMed Central. Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus
4
PubMed Central. Mechanisms of hypoglycemia unawareness and implications in diabetic patients
5
PubMed. Insulin-associated weight gain in diabetes–causes, effects and coping strategies
6
Atherosclerosis. High daily insulin exposure in patients with type 2 diabetes is associated with increased risk of cardiovascular events
7
PubMed. Basal insulin and cardiovascular and other outcomes in dysglycemia
8
PubMed. The IGF system
9
PubMed. Review on the in vitro interaction of insulin glargine with the insulin/insulin-like growth factor system
10
JAMA Oncology. Daily Insulin Dose and Cancer Risk Among Patients With Type 1 Diabetes
11
PubMed Central. Human and mouse muscle transcriptomic analyses identify insulin receptor mRNA downregulation in hyperinsulinemia-associated insulin resistance
12
PubMed Central. Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes
13
PubMed. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial
14
The Journal of Clinical Endocrinology & Metabolism. Disturbances in Insulin–Glucose Metabolism in Patients With Advanced Renal Disease With and Without Diabetes
15
PubMed. Pathophysiology and Management of Hypoglycemia in End-Stage Renal Disease Patients: A Review
16
PubMed Central. Phenolic excipients of insulin formulations induce cell death, pro-inflammatory signaling and MCP-1 release
17
PubMed. Drug intolerance reaction to insulin therapy caused by metacresol
18
PubMed. Lower glucose variability and hypoglycemia measured by continuous glucose monitoring with novel long-acting insulin LY2605541 versus insulin glargine
19
PubMed Central. Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature
20
PubMed. Combining a GLP-1 receptor agonist and basal insulin: study evidence and practical considerations
21
PubMed Central. Reduced insulin use and diabetes complications upon introduction of SGLT-2 inhibitors and GLP1-receptor agonists in low- and middle-income countries
22
PubMed Central. Animal insulin therapy induces a biased insulin antibody response that persists for years after introduction of human insulin